Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Dermata Therapeutics Inc
(NQ:
DRMA
)
1.790
-0.050 (-2.72%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Dermata Therapeutics Inc
< Previous
1
2
Next >
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 07, 2024
Via
ACCESSWIRE
Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
July 17, 2024
Via
ACCESSWIRE
Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
May 17, 2024
Via
ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 15, 2024
Via
ACCESSWIRE
Dermata to Present at the Emerging Growth Conference on April 3, 2024
March 27, 2024
Via
ACCESSWIRE
Dermata to Present at the Emerging Growth Conference on February 7, 2024
February 01, 2024
Via
ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 09, 2023
Via
ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 10, 2023
Via
ACCESSWIRE
Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
May 24, 2023
Via
ACCESSWIRE
Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
January 04, 2024
Via
ACCESSWIRE
Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
December 20, 2023
Via
ACCESSWIRE
Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols
November 16, 2023
Via
ACCESSWIRE
Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
November 16, 2023
Via
ACCESSWIRE
Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 31, 2023
Via
ACCESSWIRE
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 11, 2023
Via
ACCESSWIRE
Dermata Therapeutics Inc. (NASDAQ: DRMA) Highlighted for Surprising Price Action
March 21, 2023
Via
Investor Brand Network
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results
February 21, 2023
Via
ACCESSWIRE
Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne
June 27, 2023
Via
ACCESSWIRE
Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
June 13, 2023
Via
ACCESSWIRE
Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results
June 08, 2023
Via
ACCESSWIRE
Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
May 26, 2023
Via
ACCESSWIRE
Dermata Therapeutics Inc. (NASDAQ: DRMA) Near Top of Volume Charts in Friday Trading
May 12, 2023
Via
Investor Brand Network
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 10, 2022
Via
ACCESSWIRE
Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package
April 20, 2023
Via
ACCESSWIRE
Dermata Therapeutics Inc. (NASDAQ: DRMA) is One of Friday Morning’s Most Active Stocks
March 24, 2023
Via
Investor Brand Network
Dermata Therapeutics Announces Closing of $5.0 Million Public Offering
March 20, 2023
Via
ACCESSWIRE
Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering
March 16, 2023
Via
ACCESSWIRE
Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea
December 05, 2022
Via
ACCESSWIRE
Dermata to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022
Via
ACCESSWIRE
Dermata to Participate in the Gilmartin Group Emerging Growth Company Showcase
August 24, 2022
Via
ACCESSWIRE
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.